STXS

Over the past six months, Stereotaxis' stock has decreased by approximately 30.2%, with a 52-week trading range between $1.74 and $3.59. In November 2025, Stereotaxis reported its third-quarter financial results and announced FDA clearance for its GenesisX robotic system. In January 2026, the MAGiC catheter received FDA approval. In March 2026, Stereotaxis held its Q4 2025 earnings conference call. In April 2026, Stereotaxis announced FDA clearance and the launch of its Synchrony system, a definitive agreement to acquire Robocath, and the first successful procedures in the United States using its MAGiC catheter for complex congenital heart disease and severe cardiac arrhythmia patients.